货号 | 19520-500ug |
描述 | N-(n-Butyl)deoxygalactonojirimycin is an inhibitor of α-D-galactosidase.1 It has also been shown to prevent glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders by inhibiting the ceramide-specific glucosyltransferase, UDP-glucose ceramide glucosyltransferase (IC50 = 41.4 µM) without affecting α-glucosidase I and II or β-glucocerebrosidase (IC50s > 1 mM).1,2,3,4 This compound has been used to sensitize cultured chronic lymphocytic leukemia cells to the chemotherapeutic agents cladribine (Item No. 12085), chlorambucil, and fludarabine (Item No. 14128).5 |
别名 | Lucerastat;NBDGJ; |
供应商 | Cayman |
应用文献 | |
1.Platt, F.M.,Neises, G.R.,Karlsson, G.B., et al. N-Butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J.Biol.Chem 269(43), 27108-27114 (2016). 2.Andersson, U.,Butters, T.D.,Dwek, R.A., et al. N-butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochemical Pharmacology 59(7), 821-829 (2000). 3.Kasperzyk, J.L.,El-Abbadi, M.M.,Hauser, E.C., et al. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. Journal of Neurochemistry 89(3), 645-653 (2004). 4.Mellor, H.R.,Neville, D.C.A.,Harvey, D.J., et al. Cellular effects of deoxynojirimycin analogues: Inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochemistry Journal 381(Pt 3), 867-875 (2004). 5.Gerrard, G.,Butters, T.D.,Ganeshagurua, K., et al. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. European Journal of Pharmacology 609(1-3), 34-39 (2009). | |
运输条件 | Room temperature in continental US; may vary elsewhere |
存放说明 | -20 |
纯度 | ≥95% |
计算分子量 | 219.3 |
分子式 | C10H21NO4 |
CAS号 | 141206-42-0 |
稳定性 | ≥ 2 years |
本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。 |